Tobin Schilke

Track

Insider profile

Currently holds a position at Revance Therapeutics Inc

Performance

Overall performance
3.8
Performance over holding periods
3.8
30 days 90 days 120 days
Average return 11% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
3 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer Revance Therapeutics Inc Nov. 5, 2018 -
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer Achaogen Inc July 5, 2016 - Sept. 30, 2018
Tobin Schilke's trades of Crinetics Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-04 2026-03-03
PlS Planned sale
29,630 +31.1%
466.49
US$993,071 		29,630 +31.1% 466.49 US$993,071
2026-03-02 2026-03-02
PrS Proposed sale
4,950
164.13
US$2,616,785 		4,950 164.13 US$2,616,785
2024-03-19 2024-03-18
S Sale
72,186 +1.6%
165.15
US$2,164,071 		72,186 +1.6% 165.15 US$2,164,071
2024-03-18 2024-03-15
PrS Proposed sale
9,500
5.53
US$52,500 		9,500 5.53 US$52,500
2023-07-05 2023-07-03
PlS Planned sale
1,701 -2.1%
25.04
US$42,593 		1,701 -2.1% 25.04 US$42,593
2023-07-03 2023-07-03
PrS Proposed sale
1,701
25.04
US$42,593 		1,701 25.04 US$42,593
2023-06-05 2023-06-02
PlS Planned sale
500 -0.6%
31.00
US$15,500 		500 -0.6% 31.00 US$15,500
2023-06-02 2023-06-02
PrS Proposed sale
500
31.00
US$15,500 		500 31.00 US$15,500
2023-06-05 2023-06-01
PlS Planned sale
2,701 -3.2%
30.57
US$82,570 		2,701 -3.2% 30.57 US$82,570
2023-06-01 2023-06-01
PrS Proposed sale
2,701
30.57
US$82,570 		2,701 30.57 US$82,570
2023-05-16 2023-05-15
S Sale
21,401 -20.3%
34.55
US$739,338 		21,401 -20.3% 34.55 US$739,338
2023-05-12 2023-05-12
PrS Proposed sale
22,000
33.40
US$734,800 		22,000 33.40 US$734,800
2023-05-02 2023-05-01
PlS Planned sale
3,201 -4.8%
31.70
US$101,472 		3,201 -4.8% 31.70 US$101,472
2023-05-01 2023-05-01
PrS Proposed sale
3,201
31.70
US$101,472 		3,201 31.70 US$101,472
2023-04-04 2023-04-03
PlS Planned sale
3,201 -4.6%
32.15
US$102,912 		3,201 -4.6% 32.15 US$102,912
2023-03-09 2023-03-09
S Sale
18,517 -20.2%
31.59
US$584,884 		18,517 -20.2% 31.59 US$584,884
2023-03-09 2023-03-08
PrS Proposed sale
20,000
33.00
US$660,000 		20,000 33.00 US$660,000
2023-03-02 2023-03-01
PlS Planned sale
3,201 -6.1%
33.50
US$107,234 		3,201 -6.1% 33.50 US$107,234
2023-02-02 2023-02-01
PlS Planned sale
3,201 -5.5%
34.60
US$110,755 		3,201 -5.5% 34.60 US$110,755
2023-01-23 2023-01-20
PlS Planned sale
1,000 -1.7%
31.00
US$31,000 		1,000 -1.7% 31.00 US$31,000
2023-01-10 2023-01-09
PlS Planned sale
1,000 -1.7%
30.00
US$30,000 		1,000 -1.7% 30.00 US$30,000
2023-01-10 2023-01-09
PlS Planned sale
1,000 -1.6%
28.00
US$28,000 		1,000 -1.6% 28.00 US$28,000
2023-01-10 2023-01-09
PlS Planned sale
1,701 -2.7%
25.00
US$42,525 		1,701 -2.7% 25.00 US$42,525
2018-02-23 2018-02-21
US Achaogen Inc (AKAOQ)
PlS Planned sale
1,108 -2.7%
10.67
US$11,822 		1,108 -2.7% 10.67 US$11,822
2017-06-14 2017-06-12
US Achaogen Inc (AKAOQ)
PlS Planned sale
2,066 -4.9%
21.53
US$44,481 		2,066 -4.9% 21.53 US$44,481